Recce Pharmaceuticals Ltd
RCE
Company Profile
Business description
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.
Contact
180 George Street
Level 23
Salesforce Tower
SydneyNSW2000
AUST: +61 292562505
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,088.20 | 59.40 | 0.66% |
| CAC 40 | 7,621.04 | 10.97 | -0.14% |
| DAX 40 | 23,846.07 | 88.38 | 0.37% |
| Dow JONES (US) | 44,111.74 | 61.90 | -0.14% |
| FTSE 100 | 9,142.73 | 14.43 | 0.16% |
| HKSE | 24,902.53 | 169.08 | 0.68% |
| NASDAQ | 20,916.55 | 137.03 | -0.65% |
| Nikkei 225 | 40,529.12 | 20.42 | -0.05% |
| NZX 50 Index | 12,905.12 | 28.08 | 0.22% |
| S&P 500 | 6,299.19 | 30.75 | -0.49% |
| S&P/ASX 200 | 8,823.50 | 53.10 | 0.61% |
| SSE Composite Index | 3,617.60 | 34.29 | 0.96% |